Developing Novel CAR T Cells For Brain Cancer

HYBRID event.

VENUE: CL_15 Innovation Walk, Room G19, Meeting (Bldg 75)

ZOOM: https://monash.zoom.us/j/81357016352
ID:81357016352
Passcode:190855

NHMRC fellow, lab head, Immunology Division,
Walter and Eliza Hall Institute for Medical Research

ABSTRACT

Chimeric Antigen Receptors (CARs) are synthetic receptors composed of an antigen-binding domain fused to transmembrane and signalling domains. CARs transduced into T cells can then be directed the T cells’ endogenous recognition and killing machinery to eliminate cancer cells.

Therefore, chimeric antigen receptor (CAR) T cell therapy represents a ground-breaking approach in cancer treatment, modifying a patient’s T cells to express a CAR receptor that recognizes specific antigens on the tumour cell surface.

ABOUT THE PRESENTER

Misty Rayna Jenkins AO is an Australian scientist known for her research into lymphocytes and cancer treatment.

Jenkins leads an Immunology Laboratory at the Walter and Eliza Hall Institute of Medical Research where she researches brain cancer and aims to establish a world-leading immunotherapy lab specialising in researching the possibilities of new treatments for both adult and paediatric brain cancer.